Ginkgo Bioworks FY2023 revenue $251M (-47% YoY); guides FY2024 total revenue $215-235M

Ginkgo Bioworks Holdings, Inc.

2023-FY EPS reported -$0.46 revenue$251,455,000

Cell Engineering services revenue $139M (+31% YoY); added 78 new Cell Programs in 2023.
Biosecurity revenue $108M (-68% YoY) as K-12 testing ramped down; shifting to recurring model.
Q4 2023 total revenue $35M (-65% YoY); Q4 Adj. EBITDA loss $(96)M vs. $(76)M prior year.
Cash balance $944M; FY2024 guidance: 100-120 new Cell Programs; total revenue $215-235M.
Acquired Patch Biosciences, Proof Diagnostics, Reverie Labs; launched Technology Network of 25+ partners.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ginkgo Bioworks Holdings, Inc. reported financial results for fourth quarter 2023 and year ended December 31, 2023.

Period: fourth quarter 2023 and year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 29, 2024, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the fourth quarter 2023 and year ended December 31, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Ginkgo Bioworks Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-008045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.